Introduction {#s1}
============

Chronic liver diseases represent a major public health problem worldwide. Their prognosis greatly depends on the extent of progression leading to serious complications such as fibrosis [@pone.0069276-Starkel1]. Hepatic fibrosis is a dynamic process characterized by imbalance in production and degradation of extracellular matrix (ECM) components in the liver. The fibrotic process involves various cells and factors that lead to disruption of intercellular contacts, extracellular matrix composition and liver ability to regenerate [@pone.0069276-Poli1]. Because of significant progress in uncovering its pathogenetic mechanisms, combined with a growing realization that effective antifibrotic therapies may soon alter the history of chronic liver diseases, many candidates are now being investigated as potential therapies for fibrosis [@pone.0069276-Dhiman1]. However, a major obstacle in the development of new antifibrotic drugs is the long-term use of the drugs which dictates absence of toxicities associated with the medications. This property gives natural compounds a profound advantage [@pone.0069276-Jordan1].

Flavonoids are phenolic compounds that represent vital constituents of the human diet. With their hydroxyl groups, they possess strong antioxidative activity, making them perfect candidates to protect against various diseases [@pone.0069276-Williams1]. Their importance is further substantiated by the fact that they do not act as conventional hydrogen-donating antioxidants but may exert modulatory actions in cells through actions at various signaling pathways [@pone.0069276-Middleton1]. A clear understanding of their mechanisms of action is key to the evaluation of these potent biomolecules in treatment and prophylaxis.

BCA is an O-methylated isoflavone. It is a natural compound found in red clover, soy, alfalfa sprouts, peanuts and chickpea. A broad spectrum of biological benefits has been reported, including anti-inflammatory, antioxidative and antineoplastic effects [@pone.0069276-Mishra1].

Based on the ever-increasing list of the beneficial effects of flavonoids, and the present day need for an effective, economical and simple strategy for reversing liver injury, we planned the present study. The potential of BCA to act as antifibrotic was assessed by tackling different molecular mechanisms including effects on tumor necrosis factor-alpha (TNF-α), nuclear factor-kappa B (NF-κB) and transforming growth factor-beta1 (TGF-β1) which are attractive targets for therapeutic interventions as they represent cross-talks between cells [@pone.0069276-Salas1].

Materials and Methods {#s2}
=====================

Chemicals {#s2a}
---------

BCA, CCl~4~, dimethylsulfoxide (DMSO), p-nitrophenol, p-nitrocatechol, Ellman's reagent, chloramine-T, p-dimethylaminobenzaldehyde, indocyanine green (ICG) and thiobarbituric acid (TBA) were purchased from Sigma Chemical Co., St Louis, MO, USA. Reduced nicotinamide adenine dinucleotide phosphate (NADPH) was supplied by Sorachim Chemicals, Lausanne, Switzerland. All other chemicals used were of highest grade commercially available.

Animals and Experimental Protocol {#s2b}
---------------------------------

The study was conducted on 200--250 g male Wistar rats, supplied by the Animal Breeding Laboratory, Helwan, Egypt. All conditions were in accordance with the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines, developed by the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) and approved by the ethical committee of Ain Shams University, Egypt.

The animals were randomly divided into four groups of eight rats each. Group A served as control, taking DMSO and corn oil on alternative days and group B as the hepatotoxic model, taking intraperitoneal (IP) CCl~4~ (1 ml/kg, 1∶1 mixture with corn oil) twice weekly. Group C was given both CCl~4~ and BCA (50 mg/kg, IP dissolved in DMSO) three times per week on alternating days with CCl~4~. The dose was selected on the basis of preliminary studies, including determination of the median lethal dose (LD~50~) and the least effective hepatoprotective dose [@pone.0069276-Breikaa1]. Group D was given BCA alone. All groups were injected over a period of six weeks, then blood samples were collected from retro-orbital plexus and serum was separated by centrifugation at 1000 g for 10 min and was used for the assessment of liver functions. Rats were sacrificed by decapitation 24 h after the last injection and livers were removed and weighed, then divided into three parts: one for homogenization in saline, one put in formalin for immunohistochemical and histopathological analysis, and the last part kept as such and put together with the 20% homogenate in −80°C until needed.

Hepatic Integrity Markers and Liver Index {#s2c}
-----------------------------------------

Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), total cholesterol (TC), triglycerides (TG), alkaline phosphatase (ALP) and total bilirubin were estimated colorimetrically using available commercial kits (Spectrum diagnostics, Cairo, Egypt). Liver index was calculated according to the formula: (liver weight/body weight)×100.

Assessment of Hepatic Efficiency {#s2d}
--------------------------------

### Blood flow {#s2d1}

At the end of the six weeks, six animals per group were injected with a single dose of 3 mg/kg ICG, IP, dissolved in saline. Blood samples were collected after 10 min, 30 min, 1 h and 2 h. The plasma was separated and its optical density measured spectrophotometrically at 805 nm. The elimination rate constant (β), clearance (Cl), half-life (t~1/2~), area under the curve (AUC) and volume of distribution (Vd) were calculated. Serial dilutions of ICG (from 2.5--50 µg/ml) were prepared to construct a standard calibration curve.

### Synthetic capacity {#s2d2}

Serum albumin and total proteins (TP) were assessed colorimetrically using commercial kits (Spectrum diagnostics, Cairo, Egypt), while insulin-like growth factor-1 (IGF-1) was assessed in homogenate using enzyme-linked immunosorbent assay (ELISA) kit from R&D Systems, USA.

### Metabolic capacity {#s2d3}

Cytochrome P450 2E1 (CYP2E1) activity was assessed in homogenate colorimetrically by monitoring the formation of p-nitrocatechol from p-nitrophenol by CYP2E1. The enzymatic product, p-nitrocatechol, was assayed at 535 nm after acidification of the reaction mixture with trichloroacetic acid (TCA) followed by neutralization using 2 N NaOH [@pone.0069276-Chang1]. Assessment of cytochrome P450 1A1 (CYP1A1) expression in homogenate was done using ELISA kits from Cusabio Biotech., China. Sulfotransferase 1A1 (SULT1A1) expression was estimated by real time-polymerase chain reaction (RT-PCR). RNA was extracted from liver according to manufacturer's protocol (Qiagen, Hilden, Germany), then reverse transcribed and RT-PCR was performed using SYBR Green. Beta-Actin (β-Actin) served as internal control. Primers used were: *ratACTBF320∶5′-AGGCCCCTCTGAACCC TAAG-3′, ratACTB-R435∶5′-AGAGGCATACAGGGACAACACA-3′; rSULT1A1-F530∶5′-AGCTGAGACACACTCACCCTGTT-3′, rSULT1A1-R651∶5′-ATCCACAGTCTCCTCGGGTAGA-3′* [@pone.0069276-Chen1].

Assessment of Oxidative Stress {#s2e}
------------------------------

Lipid peroxidation was determined in homogenate by estimating level of thiobarbituric acid reactive substances (TBARS) measured as malondialdehyde (MDA), according to the method of Mihara [@pone.0069276-Mihara1]. To determine reduced glutathione (GSH), 0.5 ml homogenate was added to 0.5 ml of 10% TCA. The tubes were shaken intermittently for 15 min, followed by centrifugation at 1000 g for 10 min. An aliquot of the resulting supernatant (0.2 ml) was added to a tube containing 1.7 ml phosphate buffer and 0.1 ml Ellman's reagent then the absorbance was read at 412 nm [@pone.0069276-Ellman1]. Superoxide dismutase (SOD) and catalase (CAT) activities were determined in homogenate using commercial kits (Biodiagnostics, Cairo, Egypt). In addition, the total antioxidant capacity (TAC) was measured by providing a specific amount of exogenous H~2~O~2~ which is then reduced by antioxidants in the sample. The residual H~2~O~2~ was determined colorimetrically.

Assessment of Inflammatory Response {#s2f}
-----------------------------------

TNF-α expression was assessed using ELISA kit from RayBiotech., Inc., USA. Total nitric oxide (NO) content was estimated in homogenate spectrophotometrically by Miranda's method [@pone.0069276-Miranda1] and results were expressed as µmol/g wet tissue. Inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expressions were examined immunohistochemically. Liver sections of 4 µm were cut, then after preparing the slides, one of the following ready-to-use primary antibodies was applied: rabbit polyclonal antibody to rat iNOS (Thermoscientific, iNOS Cat\#RB-9242-R7) or rabbit polyclonal anti-rat COX-2 (Thermoscientific, COX-2 Cat\#RB-9072-R7). Examination was done with a light microscope.

Assessment of NF-κB {#s2g}
-------------------

NF-κB expression was examined immunohistochemically using rabbit polyclonal IgG to rat NF-κB p65 (SantaCruz Biotech, Cat No. sc-372).

Assessment of Fibrosis Markers {#s2h}
------------------------------

TGF-β1 was assessed using ELISA kit from R&D Systems, USA. Matrix metalloproteinase-9 (MMP-9) and alpha-smooth muscle actin (α-SMA) were examined immunohistochemically using goat polyclonal IgG to rat MMP-9 (SantaCruz Biotech, MMP-9 Cat No. sc-6840) and mouse monoclonal to rat α-SMA (SantaCruz Biotech, Cat No. sc-53142). To examine the extent of fibrosis, hydroxyproline was estimated in the liver using the simplified method of Reddy [@pone.0069276-Reddy1]. In addition, Masson's trichrome stain was used for collagen fiber detection.

Histopathologic Examination {#s2i}
---------------------------

Liver sections were stained with hematoxylin and eosin (H&E) and examined by light microscope.

Statistical Analysis {#s2j}
--------------------

Data is presented as mean ± standard deviation (SD). Multiple comparisons were performed using one-way ANOVA followed by Tukey--Kramer as a post-hoc test. Differences between groups were considered significant at p\<0.05. All statistical analyses were performed using Instat software package (version 3.06). Graphs were sketched using GraphPad Prism software (version 5).

Results {#s3}
=======

Hepatic Integrity and Liver Index {#s3a}
---------------------------------

AST and ALT increased after chronic CCl~4~ challenge by 1.8 and 1.5, respectively, compared to control group. TC and TG doubled, while levels of ALP and total bilirubin increased by 1.7 and 1.5 folds ([**Table 1**](#pone-0069276-t001){ref-type="table"}). Pretreatment with BCA normalized these levels, while BCA alone showed levels below the control group. The liver index increased in CCl~4~ group by 1.5 and decreased significantly by BCA pretreatment ([**Table 1**](#pone-0069276-t001){ref-type="table"}).

10.1371/journal.pone.0069276.t001

###### Effect of BCA on hepatic integrity markers and liver index.

![](pone.0069276.t001){#pone-0069276-t001-1}

  Group                           AST (U/L)                                        ALT (U/L)                                        TC (mg/dl)                                        TG (mg/dl)                                         ALP (U/l)                                  Total bilirubin (mg/dl)                             Liver index (%)
  ------------ ------------------------------------------------ ------------------------------------------------ ------------------------------------------------- ------------------------------------------------- -------------------------------------------------- ----------------------------------------------- -----------------------------------------------
  Control       54.3±9.29[\*\*\*](#nt104){ref-type="table-fn"}   52.4±3.73[\*\*\*](#nt104){ref-type="table-fn"}   59.5±7.58[\*\*\*](#nt104){ref-type="table-fn"}    52.7±10.13[\*\*\*](#nt104){ref-type="table-fn"}   106.7±5.22[\*\*\*](#nt104){ref-type="table-fn"}     2.6±0.21[\*\*](#nt103){ref-type="table-fn"}    2.9±0.1[\*\*\*](#nt104){ref-type="table-fn"}
  CCl~4~                          80.4±11.93                                        95±26.47                                        108.2±22.78                                       112.6±38.55                                        181.1±42.8                                        3.8±0.95                                        4.3±0.41
  BCA+CCl~4~    48±10.26[\*\*\*](#nt104){ref-type="table-fn"}     69.2±7.27[\*\*](#nt103){ref-type="table-fn"}    69.4±10.95[\*\*\*](#nt104){ref-type="table-fn"}     73±17.48[\*\*](#nt103){ref-type="table-fn"}     107.7±11.88[\*\*\*](#nt104){ref-type="table-fn"}    2.6±0.41[\*\*](#nt103){ref-type="table-fn"}     3.8±0.19[\*\*](#nt103){ref-type="table-fn"}
  BCA           42.1±4.55[\*\*\*](#nt104){ref-type="table-fn"}    50±8.07[\*\*\*](#nt104){ref-type="table-fn"}    59.7±11.31[\*\*\*](#nt104){ref-type="table-fn"}   43.7±14.5[\*\*\*](#nt104){ref-type="table-fn"}    101.5±9.31[\*\*\*](#nt104){ref-type="table-fn"}    2.5±0.58[\*\*\*](#nt104){ref-type="table-fn"}   2.9±0.29[\*\*\*](#nt104){ref-type="table-fn"}

n = 8.

p\<0.05 compared to CCl~4~ group.

p\<0.01 compared to CCl~4~ group.

p\<0.001 compared to CCl~4~ group.

Hepatic Efficiency {#s3b}
------------------

### Blood flow {#s3b1}

ICG elimination rate decreased to the half by CCl~4~ challenge, while the clearance decreased by 23%, compared to control group. Its t~1/2~, AUC and Vd significantly increased by about 4 folds, 1.4 folds and 3.2 folds, respectively ([**Table 2**](#pone-0069276-t002){ref-type="table"}). BCA pretreatment, however, increased the elimination and the clearance by 1.5 folds and 1.2 folds, as compared to CCl~4~ group. T~1/2~, AUC and Vd decreased with BCA by 3, 1.3 and 2.7 folds in comparison to CCl~4~ group.

10.1371/journal.pone.0069276.t002

###### Effect of BCA on ICG pharmacokinetics.

![](pone.0069276.t002){#pone-0069276-t002-2}

  Group                          β (hr^−1^)                                      t~1/2~ (hr)                                      AUC (hr.µg/ml)                                   Cl (ml/kg/hr)                                     Vd (ml/kg)
  ------------ ---------------------------------------------- -------------------------------------------------- ------------------------------------------------ ------------------------------------------------ -----------------------------------------------
  Control       39±5.4[\*\*\*](#nt109){ref-type="table-fn"}    0.026±0.008[\*\*\*](#nt109){ref-type="table-fn"}   209.2±24.75[\*\*](#nt108){ref-type="table-fn"}   15.3±0.97[\*\*\*](#nt109){ref-type="table-fn"}   0.6±0.21[\*\*\*](#nt109){ref-type="table-fn"}
  CCl~4~                         18.7±2.34                                       0.101±0.023                                        291.1±41.6                                       11.8±0.39                                        1.9±0.62
  BCA+CCl~4~                      27.5±6.1                     0.032±0.007[\*\*\*](#nt109){ref-type="table-fn"}    223.3±36.82[\*](#nt107){ref-type="table-fn"}      14.6±2[\*\*](#nt108){ref-type="table-fn"}      0.7±0.19[\*\*\*](#nt109){ref-type="table-fn"}
  BCA           32.4±9.93[\*\*](#nt108){ref-type="table-fn"}   0.029±0.008[\*\*\*](#nt109){ref-type="table-fn"}     227±28.93[\*](#nt107){ref-type="table-fn"}       14.2±1.43[\*](#nt107){ref-type="table-fn"}     0.5±0.13[\*\*\*](#nt109){ref-type="table-fn"}

β (elimination rate constant), Cl (clearance), t~1/**2**~ (elimination half-life) and AUC (area under the curve).

n = 6.

p\<0.05 compared to CCl~4~ group.

p\<0.01 compared to CCl~4~ group.

p\<0.001 compared to CCl~4~ group.

### Synthetic capacity {#s3b2}

Albumin, TP and IGF-1 were depleted by chronic CCl~4~ intoxication, where TP reached half and IGF-1 1/16 of the control levels. BCA pretreatment significantly prevented their depletion ([**Table 3**](#pone-0069276-t003){ref-type="table"}).

10.1371/journal.pone.0069276.t003

###### Effect of BCA on hepatic synthetic capacity.

![](pone.0069276.t003){#pone-0069276-t003-3}

  Group                      Albumin (g/dl)                                   TP (g/dl)                                   IGF-1 (pg/mg protein)
  ------------ ------------------------------------------- ----------------------------------------------- ----------------------------------------------------
  Control                       3.1±0.52                    6.6±1.06[\*\*\*](#nt113){ref-type="table-fn"}   2674.5±319.87[\*\*\*](#nt113){ref-type="table-fn"}
  CCl~4~                        2.4±0.43                                      3.4±0.99                                         161.4±53.51
  BCA+CCl~4~    3.3±0.91[\*](#nt111){ref-type="table-fn"}   5.4±0.81[\*\*\*](#nt113){ref-type="table-fn"}   1053.8±144.63[\*\*\*](#nt113){ref-type="table-fn"}
  BCA           3.4±0.31[\*](#nt111){ref-type="table-fn"}   5.6±0.81[\*\*\*](#nt113){ref-type="table-fn"}   2583.9±331.63[\*\*\*](#nt113){ref-type="table-fn"}

n = 8.

p\<0.05 compared to CCl~4~ group.

p\<0.01 compared to CCl~4~ group.

p\<0.001 compared to CCl~4~ group.

### Metabolic capacity {#s3b3}

The activity of CYP2E1 increased in CCl~4~ group by 10%, as compared to control ([**Fig. 1**](#pone-0069276-g001){ref-type="fig"}). The pretreatment with BCA significantly reduced the activity even below levels of control.

![Effect of BCA on hepatic metabolic capacity.\
(**A**) CYP2E1 activity levels; (**B**) CYP1A1 expression levels; (**C**) SULT1A1 relative quantitation (RQ) versus group mean plot. *a*: significantly different from control gp. *b*: significantly different from CCl~4~ gp.](pone.0069276.g001){#pone-0069276-g001}

In addition, the expression of CYP1A1 was significantly higher after chronic CCl~4~ challenge, while it approached normal levels by BCA pretreatment ([**Fig. 1**](#pone-0069276-g001){ref-type="fig"}). The group treated with BCA alone showed levels that reach one third of control group. RT-PCR results showed increased expression of SULT1A1 in all groups compared to control ([**Fig. 1**](#pone-0069276-g001){ref-type="fig"}). However, increases in CCl~4~ and pretreated group were higher than BCA alone suggesting that not only BCA increased the expression, but also the CCl~4~ challenge did.

Oxidative Stress Markers {#s3c}
------------------------

CCl~4~ increased MDA level by 62%, while GSH was severely depleted, reaching about 11% of the control level. The TAC decreased by 41%, as compared to control group ([**Table 4**](#pone-0069276-t004){ref-type="table"}). Animals pretreated with BCA showed near normal MDA and TAC levels. The dramatic depletion of GSH was reversed and even increased by 19% above control, while BCA alone increased GSH level by 31%. Furthermore, SOD and CAT activities were suppressed by CCl~4~ and returned to normal levels by BCA ([**Table 4**](#pone-0069276-t004){ref-type="table"}).

10.1371/journal.pone.0069276.t004

###### Effect of BCA on oxidative stress markers.

![](pone.0069276.t004){#pone-0069276-t004-4}

  Group                          MDA (nmol/g)                                    GSH (µmol/g)                                       TAC (µmol/g)                                        SOD (U/mg)                                         CAT (U/g)
  ------------ ------------------------------------------------ ----------------------------------------------- ---------------------------------------------------- ------------------------------------------------- --------------------------------------------------
  Control        11±1.32[\*\*\*](#nt117){ref-type="table-fn"}     6±2.1[\*\*\*](#nt117){ref-type="table-fn"}     0.0032±0.0005[\*\*\*](#nt117){ref-type="table-fn"}   55.7±11.71[\*\*\*](#nt117){ref-type="table-fn"}   898.9±56.55[\*\*\*](#nt117){ref-type="table-fn"}
  CCl~4~                          17.7±2.81                                        0.7±0.23                                        0.0019±0.0006                                          21±6.31                                          640±73.72
  BCA+CCl~4~    11.6±0.96[\*\*\*](#nt117){ref-type="table-fn"}    7.2±2[\*\*\*](#nt117){ref-type="table-fn"}     0.0033±0.0002[\*\*\*](#nt117){ref-type="table-fn"}    51.5±7.8[\*\*\*](#nt117){ref-type="table-fn"}    899.1±85.63[\*\*\*](#nt117){ref-type="table-fn"}
  BCA           11.5±0.74[\*\*\*](#nt117){ref-type="table-fn"}   7.9±1.97[\*\*\*](#nt117){ref-type="table-fn"}   0.0035±0.0002[\*\*\*](#nt117){ref-type="table-fn"}    51.4±6.3[\*\*\*](#nt117){ref-type="table-fn"}    896.7±40.95[\*\*\*](#nt117){ref-type="table-fn"}

n = 8.

p\<0.05 compared to CCl~4~ group.

p\<0.01 compared to CCl~4~ group.

p\<0.001 compared to CCl~4~ group.

Inflammation Markers {#s3d}
--------------------

TNF-α and total NO in CCl~4~ group reached 138% and 163% of control group, respectively. BCA restored their levels ([**Fig. 2 A & B**](#pone-0069276-g002){ref-type="fig"}). Immunohistochemical staining showed extensive expression of COX-2 and iNOS in CCl~4~ group, while the pretreated group showed marked reduction ([**Fig. 3 A & B**](#pone-0069276-g003){ref-type="fig"}). The control and BCA model group showed minimal expression.

![Effect of BCA on TNF-α, NO and TGF- β1 levels.\
(**A**) TNF-α expression levels; (**B**) NO levels; **(C)** TGF- β1 expression levels. *a*: significantly different from control gp. *b*: significantly different from CCl~4~ gp.](pone.0069276.g002){#pone-0069276-g002}

![Representative images of liver sections of different experiments.\
(**A--E**): Immunohistochemical detection of COX-2, iNOS, NF-κB, MMP-9 and α-SMA (x100). Control gp: minimal expression; CCl~4~ gp: extensive expression; BCA+CCl~4~ gp: less than CCl~4~ gp; BCA gp: minimal expression. Image analysis was performed by examining 6 fields/slide. (**F**): Masson trichrome stain (x40). Control gp: shows absence of collagen fibers (stained blue) between hepatic lobules; CCl~4~ gp: extensive fibers deposition with pseudolobules formation (bridging fibrosis); BCA+CCl~4~ gp: less fibers than CCl~4~ gp; BCA gp: absence of fibers. The bar chart represents levels of hydroxyproline expressed as µg/gm of wet tissue measured by Reddy's method. *a*: significantly different from control gp. *b*: significantly different from CCl~4~ gp.](pone.0069276.g003){#pone-0069276-g003}

Effect on NF-κB {#s3e}
---------------

Control rats showed minimal immunostaining ([**Fig. 3 C**](#pone-0069276-g003){ref-type="fig"}), while CCl~4~ group showed significant expression. Pretreatment with BCA significantly inhibited its expression. BCA alone showed expression levels below control group.

Fibrosis Markers {#s3f}
----------------

Fibrosis was first evaluated by measuring TGF-β1 expression which increased by 1.8 folds in CCl~4~ group, while levels decreased by 30% by BCA pretreatment, compared to the CCl~4~ group ([**Fig. 2 C**](#pone-0069276-g002){ref-type="fig"}). Immunohistochemistry revealed high MMP-9 ([**Fig. 3 D**](#pone-0069276-g003){ref-type="fig"}) and α-SMA ([**Fig. 3 E**](#pone-0069276-g003){ref-type="fig"}) in CCl~4~ group. Furthermore, high hydroxyproline levels were detected with dense blue color in Masson's slides around and inbetween portal tracts and central veins, indicating pseudolobules formation ([**Fig. 3 F**](#pone-0069276-g003){ref-type="fig"}). Significantly lower levels were found in the other groups.

Histopathology {#s3g}
--------------

CCl~4~ caused marked necrosis with fatty deposits and ballooning degeneration, associated with extensive fibrosis and inflammatory cells infiltration ([**Fig. 4**](#pone-0069276-g004){ref-type="fig"}). BCA significantly ameliorated these changes. Sections from control and BCA model group showed normal hepatic architecture with polyhedral hepatocytes and prominent nuclei. The histopathological findings were scored by a histopathologist.

![Histopathological findings followed by grading of liver damage.\
(x40) (**A**) control: normal histological structure of portal area and surrounding hepatocytes; (**B**) CCl~4~: loss of architecture with severe ballooning degeneration (arrow1), necrosis (arrow2) and fatty changes (arrow3) accompanied with fibrosis; (**C**) BCA+CCl~4~: much less damage than in CCl~4~ gp (**D**) BCA alone: similar to control gp.](pone.0069276.g004){#pone-0069276-g004}

Discussion {#s4}
==========

Hepatic fibrosis is the consequence of wound-healing response of the liver to repeated injury resulting in accumulation of tough, fibrous scar tissue [@pone.0069276-Friedman1]. It develops with different spatial patterns according to causes of the parenchymal damage. Key events are the propagation of oxidative and inflammatory responses with subsequent transformation of quiescent hepatic stellate cells (HSCs) into myofibroblast-like cells [@pone.0069276-Parola1].

Flavonoids are phenolic compounds that represent vital constituents of the human diet. With their hydroxyl groups, they possess strong antioxidative activity, making them perfect candidates to protect against various diseases [@pone.0069276-Williams1]. Their importance is further substantiated by the fact that they do not act as conventional hydrogen-donating antioxidants but may exert modulatory actions in cells through actions at various signaling pathways [@pone.0069276-Middleton1]. A clear understanding of their mechanisms of action is key to the evaluation of these potent biomolecules in treatment and prophylaxis. BCA is a natural isoflavone with multiple pharmacological activities, including antihyperglycemic, anti-inflammatory and antioxidative effects [@pone.0069276-Harini1], [@pone.0069276-Kole1]. A study by Badria et al has shown that BCA inhibits HSC proliferation, thus pointing to a potential antifibrotic activity [@pone.0069276-Badria1].

Events of hepatic fibrosis were simulated in this study using a CCl~4~-induced fibrosis model. First, to ensure development of fibrosis by CCl~4~ and its decrease by BCA, collagen deposition was determined both biochemically and histologically by visualizing the blue color of collagen fibers using Masson's stain. Both confirmed fibrotic lesions after CCl~4~ challenge and minimal deposition with BCA. In addition, the fact that BCA was able to decrease α-SMA, a marker of activated HSCs, confirms its antifibrotic effect [@pone.0069276-Teraoka1].

The mechanisms underlying this antifibrotic activity were then examined thoroughly. High AST, ALT, TC and TG levels confirmed CCl~4~-induced hepatocellular damage. High ALP and total bilirubin indicated dysfunction of hepatocytes and increased biliary pressure. The reversal of these alterations by BCA is a clear indication of the improvement of the functional status of hepatocytes with preservation of cellular architecture [@pone.0069276-Tatiya1].

In an attempt to investigate possible changes in liver efficiency, hepatic blood flow, synthetic and metabolic capacities were examined. Effect on blood flow was investigated by assessing changes in ICG pharmacokinetics which is exclusively eliminated by the liver without metabolic modifications or enterohepatic recirculation. Furthermore, its presence in the blood can be accurately assessed in presence of hyperbilirubinemia [@pone.0069276-Hsieh1]. Thus, the rate limiting step for ICG elimination is the hepatic blood flow [@pone.0069276-Tralhao1]. CCl~4~ clearly decreased the elimination of ICG, reflecting compromised blood flow which can be attributed to the necrotic effect of CCl~4~ causing irreversible damage of microvascular circulation, in addition to excessive deposition of collagen fibers in extracellular spaces, causing hindered blood infusion [@pone.0069276-Suzuki1]. BCA successively improved the blood flow. The hepatic synthetic capacity was evaluated by measuring albumin, TP and IGF-1, all of which are synthesized in the liver. Chronic CCl~4~ challenge caused their severe depletion, while BCA restored their levels. Owing to its unique vascular and metabolic features, the liver is exposed to many xenobiotics, which are either activated or detoxified by drug-metabolizing enzymes [@pone.0069276-Jaeschke1]. CYP2E1 is one principal member of the phase I metabolizing enzymes, the cytochrome P450 (CYP450) family, responsible for bioactivation of many xenobiotics, including CCl~4~ [@pone.0069276-Manibusan1]. BCA was found to affect the activity of CYP2E1 and even inhibit it to levels lower than those of the control group, thus, allowing BCA to suppress the bioactivation of various xenobiotics. In addition to CYP2E1, CYP1A1 is another important P450 enzyme causing propagation of liver injury, with marked role in oxidative stress by excessive generation of reactive oxygen species (ROS) [@pone.0069276-Chan1], [@pone.0069276-Dutta1]. SULT1A1 was chosen as a phase II enzyme helping the liver to get rid of xenobiotics [@pone.0069276-Moon1]. Our study revealed increase of CYP1A1 expression by chronic CCl~4~ injection associated with decrease by BCA, while SULT1A1 increased both by BCA and CCl~4~, suggesting that sulfotransferases can act as defense against a xenobiotic challenge as CCl~4~.

Oxidative stress produced by free radicals is the main and primary step in CCl~4~ toxicity contributing to both onset and progression of fibrosis [@pone.0069276-Boll1]. This was evidenced by enhanced lipid peroxidation, associated with low levels of GSH which represents the non-enzymatic part of the antioxidant defense of the body [@pone.0069276-Fang1]. The enzymatic part was represented in our study with SOD and CAT. The activities of both enzymes were reduced by CCl~4~. Since it became clear that the cooperation among different antioxidants provides greater protection against attack by ROS and free radicals than any single compound alone, the overall antioxidant capacity may provide more accurate information compared to that obtained by the measurement of individual components, as it considers the cumulative effect of all antioxidants present in the liver [@pone.0069276-Ghiselli1]. As expected, CCl~4~ markedly decreased the TAC. Flavonoids are potent molecules that donate a hydrogen atom from an aromatic hydroxyl group to a free radical, yielding a stable phenolic radical. Furthermore, their amphiphilicity enhances their ability to trap chain-initiating radicals at the interface of the membranes, preventing progression of the radical chain reaction [@pone.0069276-Bandy1]. BCA indeed showed superior antioxidant activity evident by TAC levels above control group.

Another pathway involved in fibrosis is the inflammatory process that is initiated by activation of Kupffer cells, which further release a number of proinflammatory mediators like TNF-α [@pone.0069276-Racanelli1]. The heightened inflammatory response following CCl~4~ injection was evident by increased levels of TNF-α, which was significantly attenuated by BCA. NO plays crucial roles in inflammation and liver injury [@pone.0069276-Leung1]. It is produced in large quantities by Kupffer cells, endothelial cells and the hepatocytes themselves in response to tissue damage and inflammation induced by various xenobiotics including CCl~4~. In addition, its role in oxidative stress cannot be neglected, since high levels of NO have been associated with oxidative injury via lipid peroxide.

production and antioxidant consumption [@pone.0069276-Zimiani1]. Our findings confirmed elevated NO in the CCl~4~ group, while BCA caused decreased levels. Two enzymes responsible for initiation and propagation of the inflammatory cascade are iNOS [@pone.0069276-Zhu1] and COX-2 which accounts for the increased production of PGs in response to proinflammatory stimuli [@pone.0069276-Hu1]. Inhibition of iNOS and COX-2 expressions were found to be two mechanisms by which BCA can act as an anti-inflammatory, thereby protecting the liver. Furthermore, sustained hepatic inflammation provoked by long-term intoxication with CCl~4~ is believed to be through NF-kB pathway [@pone.0069276-Sunami1], [@pone.0069276-Palanisamy1]. NF-κB is a pleiotropic protein with pivotal role in controlling cell signaling under certain physiological and pathological conditions [@pone.0069276-Muriel1]. In this context, activation of many kinases involved in NF-κB pathway is shown to be dependent on oxidative stress [@pone.0069276-Castello1], where ROS have been shown to cause prolonged NF-κB DNA binding activity [@pone.0069276-Gloire1], [@pone.0069276-Morgan1]. Further, Kupffer cells display powerful NF-κB activation in response to liver injury by CCl~4~, resulting in production and secretion of proinflammatory cytokines and profibrogenic mediators such as TGF-β1 [@pone.0069276-Racanelli1]. TGF-β1 is a multifunctional growth factor stimulating synthesis and deposition of ECM components, in addition to favoring transition of hepatocytes to myofibroblast-like cells [@pone.0069276-Liu1]. Thus, in our study, both NF-κB and TGF-β1 were found upregulated in fibrotic lesions, while BCA decreased their expression.

Quantitative and qualitative changes in matrix degrading activity play an important role in ECM remodeling and accumulation of ECM components accompanying liver fibrosis [@pone.0069276-Okamoto1].

A large family of MMPs has been characterized that is responsible for degrading collagens [@pone.0069276-Veidal1]. However, high levels of MMPs cause excessive degradation of normal subendothelial ECM hastening its replacement by fibrous collagen, which further activates stellate cells in a positive feedback loop [@pone.0069276-Theret1]. Furthermore, MMP-induced degradation of the ECM releases previously sequestered growth factors that can induce a variety of biological responses including inflammation [@pone.0069276-Belotti1]. One member of this family is MMP-9 which is considered a hallmark of fibrosis [@pone.0069276-Vassiliadis1] and whose expression increases by TNF-α and TGF-β1 during the onset of liver fibrogenesis [@pone.0069276-Han1]. MMP-9 increased by CCl~4~, which could be one of the reasons for aggravating its hepatotoxicity.

In light of all the previous findings, the present study provides evidence for the hepatoprotective and antifibrotic effects of BCA. The mechanisms underlying these promising effects involve attenuating oxidative stress, as well as decreasing the expression of NF-κB and the subsequent inflammatory cascade and the production of profibrogenic factors. The net effect is, thus, preservation of the hepatocellular integrity and the hepatic efficiency.
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